Randomized controlled trials of acute reduction in plasma fibrinogen with a defibrinating snake venom enzyme, ancrod
, have shown reductions in the risk for venous thromboembolism in surgical and stroke patients and a reduction in cerebral infarct size in acute ischemic stroke (6); however, the benefit of the latter effect was outweighed by an increased risk of intracranial bleeding.
Heparine bagli trombositopeni gelisen hastalarda KPB sirasinda antikoagulasyon icin danaparoid, ancrod
ve recombinant hirudin tercih edilebilir.
NTI) (Nasdaq: NTII) announced today the presentation of new analysis of data from prior clinical trials of ancrod
and updates on the clinical development of their investigational drug, Viprinex(TM) (ancrod
), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom.
) is currently being studied in two Phase III global trials known as Ancrod
Stroke Program I (ASP-I) and Ancrod
Stroke Program II (ASP-II).
Key members of the Nordmark team produced the product while employed by the former Knoll AG, the previous manufacturer of ancrod
One trial of 500 patients reached statistical significance for improved outcome when ancrod
was started within 3 hours of symptom onset, and larger trials in Europe and China are planned.
is less likely to cause internal bleeding than existing drugs and it can also protect against further strokes, by lowering levels of clotting substances in the blood.
8,34,97] On the basis of these disappointing results, new approaches have been proposed that have included the use of LMWH, heparinoids, anticoagulating agents such as ancrod
, prostaglandin (Iloprost), antiplatelet drugs, and thrombin inhibitors (argatroban and hirudin).
In a study of 500 stroke patients, 42percent who were given the drug ancrod
within three hours regained significant functioning.
TPA may be more effective, but ANCROD
may have fewer bleeding complications.
has been approved for use in Canada for treatment of phlebitis.
Other options include ancrod
(snake venom with antifibrinolytic activity), danaparoid (heparin, chrondroitin, and dermatan), and plasmapheresis.